Strategic Investment Committee
Caroline Moon
Chief Financial Officer, Scripps Research
With over 25 years of financial leadership experience in the technology sector, Caroline brings a broad and deep skill set in financial strategy and operations, as well as digital transformation. She joined Scripps Research in 2022, coming from a position as the Head of Strategic Finance at the Broad Institute of MIT and Harvard, where she gained an intimate understanding of this top biomedical research institute. Prior to the Broad, she was a partner at the venture capital firm Andreessen Horowitz, where she provided strategic guidance and finance best practices to the executive leadership teams at the firm’s portfolio companies, having served as CFO to a number of early- to growth-stage technology companies before joining the firm.
Marshall Olin, Esq
General Counsel, Scripps Research
In his current role, Marshall leverages his extensive legal expertise to support the institute’s groundbreaking scientific endeavors and its commercialization and company formation efforts. Prior to joining Scripps Research, Marshall spent time at Latham and Watkins and Cooley LLP, as part of their respective life sciences partnering / technology transfer groups. His practice focuses on complex licensing, collaboration agreements and corporate finance, for a diverse range of clients, including biotech, university, non-profit, venture and large pharma.
Ming Cheah, PhD
Biotech Investor, Goldman Sachs
Ming specializes in Life Sciences Investing in the San Francisco Bay Area. With a PhD from Stanford University School of Medicine and experience at Genentech, he has expertise in immunology, biotechnology, data analysis, and strategy, and has held key roles in various biotech companies and investment firms.
Shawn Fu, MD
Vice President, CorpDev and Head of Strategy, SonoThera
Shawn brings with him a wide array of experience ranging from his training as an Anesthesiologist to time spent in consulting, equity research and Venture Capital. Prior to joining SonoThera, he was a Vice President at Vertex Ventures HC focusing on platform technologies and genetic medicines where he led investments and held board positions across both biotech & medtech opportunities. Shawn also served as Vice President on JP Morgan’s Equity Research desk.
Leighanne Oh, MS
Vice President, Ascenta Capital
Leighanne is focused on discovering and evaluating new investment opportunities, leveraging her private and public investing experience and operating background. Before joining Ascenta, Leighanne spent the last 5 years investing in biotech and life sciences companies at Novo Holdings and Sofinnova Investments. Leighanne started her investing career at SoBE Bioequities (Sofinnova’s L/S hedge fund), focusing on public investments in global biotech and pharmaceutical companies. She later served on Sofinnova’s investment committee as a private investor focused on clinical stage investments from 2019 – 2022 and at Novo Holdings from 2022-2024. Before that, Leighanne began her career as an Analyst on the Healthcare Investment Banking team at Jefferies. In that role, she focused on M&A, public and private capital raising, licensing deals, and a wide scope of advisory work for biotechnology and pharmaceutical companies. Trained as a protein and biomedical engineer, Leighanne also brings her operating background as a manufacturing engineer from GE Healthcare.
Emily Park, MD
Principal, DCVC Bio
Emily works to unlock later-stage value in early-stage therapeutics platform and computational biology companies, with a focus on strategic pipeline and drug development. She also provides strategic and operational guidance and fundraising support to DCVC Bio’s portfolio companies, empowering them to reach key milestones and realize their complete growth potential. Prior to joining DCVC Bio, Emily worked in the public markets, as a biotech equities analyst at Point72 Asset Management and on the Global Investment Research team at Goldman Sachs, where she conducted deep-dive analyses on early-stage therapeutics and clinical trial catalysts across multiple disease areas for SMID-Cap biotech and pharma stocks. She has also done independent consulting for hedge funds and TechBio companies, where she has worked with executive teams on business development and capital fundraising.
